Efficacy of Denosumab vs Zoledronic Acid in Patients with BC and Bone Mets and Safety Analysis of Bev Plus Bisphosphonates in Met BC


Efficacy of Denosumab vs Zoledronic Acid in Patients with BC and Bone Mets and Safety Analysis of Bev Plus Bisphosphonates in Met BC
Slides from presentations at SABCS 2010 and transcribed comments from Lisa A Carey, MD (12/12/10) and a recent interview with William J Gradishar, MD (1/4/11)
Ngamphaiboon N et al. Osteonecrosis of the jaw: Dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab at Roswell Park Cancer Institute. San Antonio Breast Cancer Symposium 2010;Abstract P2-13-03.

Stopeck A et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: Results from the extended blinded treatment phase. San Antonio Breast Cancer Symposium 2010;Abstract P6-14-01.

Dr Carey is Medical Director of the UNC Breast Center at the University of North Carolina at Chapel Hill’s Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina.

Dr Gradishar is Director of Breast Medical Oncology at the Robert H Lurie Comprehensive Cancer Center and Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.